What Analysts Recommend for BioMarin Pharmaceuticals in September
In August 2017, BioMarin Pharmaceuticals (BMRN) and Sarepta Therapeutics (SRPT) entered a license agreement that gives Sarepta Therapeutics exclusive worldwide rights to BioMarin Pharmaceuticals’ DMD (duchenne muscular dystrophy) patents for EXONDYS 51 and all upcoming exon-skipping products. However, BioMarin Pharmaceuticals retains the right to convert the license to a co-exclusive right when the company decides to proceed with an exon-skipping therapy for DMD.
In August 2017, the U.S. Food and Drug Administration accepted the Biologics License Application (or BLA) for BioMarin Pharmaceuticals’ pegvaliase and has selected it for priority review. Pegvaliase is a PEGylated recombinant phenylalanine ammonia lyase enzyme that can reduce blood phenylalanine levels in adults with phenylketonuria (or PKU) and have uncontrolled blood phenylalanine levels on existing therapy. The FDA has granted the Prescription Drug User Fee Act (or PDUFA) action date of February 28, 2018.
Interested in BIIB? Don't miss the next report.
Receive e-mail alerts for new research on BIIB
Twenty-two analysts are tracking BioMarin Pharmaceuticals in September 2017. Seven analysts suggested a “strong buy,” while ten analysts suggested a “buy.” Five of them suggested a “hold, ” and none of them suggested a “sell” or “strong sell.”
About 77.2% of analysts tracking BioMarin Pharmaceuticals in September 2017 suggested some form of a “buy” rating. On September 7, 2017, BioMarin Pharmaceuticals had a consensus 12-month target price of $111.50, which represents a ~23.3% return on investment. The PowerShares QQQ (QQQ) invests ~0.23% of its total portfolio holdings in BioMarin Pharmaceuticals.
Twenty-seven analysts are analyzing Biogen (BIIB) in September 2017. Around 63% of the analysts recommended some form of a “buy” rating. Ten analysts suggested a “hold,” and none of the analysts suggested any form of a “sell” or “strong sell.” On September 7, 2017, Biogen had a consensus 12-month target price of $327.55, which represents a ~1.1% return on investment.
Five analysts are analyzing Syros Pharmaceuticals (SYRS) in September 2017. Two analysts recommended a “strong buy,” while one analyst recommended a “buy.” Two analysts suggested a “hold,” while none of the analysts suggested any form of a “sell” or “strong sell.” On September 7, 2017, Syros Pharmaceuticals had a consensus 12-month target price of around $26.50, which represents a ~56.0% return on investment.